TMCnet News
Four Clinical Trials in Progress; New Drug Candidates in Laboratory TestingOXFORD & NEWCASTLE, United Kingdom --(Business Wire)-- e-Therapeutics plc (AIM:ETX), the drug discovery and development company, today announces its half year results for the six months ended 31 July 2014. Operational highlights Cancer trials for lead cancer drug ETS2101 continue
Progress on other programmes - ETS6103 and ETX1153c
Accelerated rate of drug analysis by Network Pharmacology Discovery platform
Professor Malcolm Young, CEO of e-Therapeutics, said: "As our clinical programmes continue apace in four current clinical trials, a further key change for the Company in the period has been the tangible acceleration in processing speeds and productivity of our Discovery platform based on network pharmacology. Over the past two years, we have been fortunate to receive significant funding to invest in the discovery engine. We are now seeing the results of this investment, from network analysis processing speeds that are 20 times faster to a greatly enhanced database of protein interaction and compound bioactivity data. We will select the most promising compounds and expect them to enter preclinical development by the end of H2 2015 to enter the clinic in 2017. "Professor James has indicated that he will retire at the end of 2014. On behalf of the Company, I would like thank Oliver for his long and sterling service to the Company, and wish him a pleasant retirement. A further announcement about succession will be made in due course. "e-Therapeutics is in a strong position to deliver shareholder value as it capitalises on fully functioning drug discovery and clinical development programmes with a strong balance sheet. We look forward to providing further updates in the short term on our development programmes and in the medium term on our discovery activities." For the full release, please visit the company website at www.etherapeutics.co.uk.
|